- Home
- TVRD vs GALT Comparison
TVRD vs GALT Comparison
Compare TVRD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- GALT
- Stock Information
- Founded
- TVRD 2017
- GALT 2000
- Country
- TVRD United States
- GALT United States
- Employees
- TVRD N/A
- GALT N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- GALT Health Care
- Exchange
- TVRD Nasdaq
- GALT Nasdaq
- Market Cap
- TVRD 246.5M
- GALT 232.3M
- IPO Year
- TVRD N/A
- GALT N/A
- Fundamental
- Price
- TVRD $4.39
- GALT $5.67
- Analyst Decision
- TVRD Buy
- GALT Strong Buy
- Analyst Count
- TVRD 7
- GALT 3
- Target Price
- TVRD $51.67
- GALT $6.00
- AVG Volume (30 Days)
- TVRD 718.4K
- GALT 339.7K
- Earning Date
- TVRD 11-21-2025
- GALT 11-14-2025
- Dividend Yield
- TVRD N/A
- GALT N/A
- EPS Growth
- TVRD N/A
- GALT N/A
- EPS
- TVRD N/A
- GALT N/A
- Revenue
- TVRD N/A
- GALT N/A
- Revenue This Year
- TVRD N/A
- GALT N/A
- Revenue Next Year
- TVRD N/A
- GALT N/A
- P/E Ratio
- TVRD N/A
- GALT N/A
- Revenue Growth
- TVRD N/A
- GALT N/A
- 52 Week Low
- TVRD $4.40
- GALT $0.73
- 52 Week High
- TVRD $43.65
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- TVRD 19.50
- GALT 62.88
- Support Level
- TVRD $4.63
- GALT $5.04
- Resistance Level
- TVRD $5.00
- GALT $5.36
- Average True Range (ATR)
- TVRD 0.45
- GALT 0.33
- MACD
- TVRD 0.22
- GALT 0.05
- Stochastic Oscillator
- TVRD 0.35
- GALT 60.81
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.